# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner ViatrisFARMINGTON HILLS, Mich., Apr...
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the ...
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confid...
Alliance Global Partners analyst James Molloy maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target...
HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price...
Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.210) per share which missed the analyst consensus estimate of $(...
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief...
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercial...